You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Investigational Drug Information for Chidamide


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Chidamide?

Chidamide is an investigational drug.

There have been 156 clinical trials for Chidamide. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2019.

The most common disease conditions in clinical trials are Lymphoma, Lymphoma, T-Cell, and Lymphoma, T-Cell, Peripheral. The leading clinical trial sponsors are Sun Yat-sen University, Chinese PLA General Hospital, and Chipscreen Biosciences, Ltd.

There are five US patents protecting this investigational drug and twenty-eight international patents.

Recent Clinical Trials for Chidamide
TitleSponsorPhase
SHR2554 Clinical Study of Chidamide in the Treatment of T-cell LymphomaJiangsu HengRui Medicine Co., Ltd.Phase 3
Tucidinostat Plus Apatinib for Advanced OsteosarcomaWuhan Union Hospital, ChinaPhase 2
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell LymphomaDongguan People's HospitalPhase 2

See all Chidamide clinical trials

Clinical Trial Summary for Chidamide

Top disease conditions for Chidamide
trials010203040506070LymphomaLymphoma, T-CellLymphoma, T-Cell, Peripheral[disabled in preview]
Top clinical trial sponsors for Chidamide
trials024681012141618202224Sun Yat-sen UniversityChinese PLA General HospitalChipscreen Biosciences, Ltd.[disabled in preview]

See all Chidamide clinical trials

US Patents for Chidamide

DrugnamePatent NumberPatent TitlePatent AssigneeEstimated Expiration
Chidamide ⤷  Subscribe 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors Shenzhen Chipscreen Biosciences Ltd. (Shenzhen, CN) ⤷  Subscribe
Chidamide ⤷  Subscribe Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors Shenzhen Chipscreen Biosciences Ltd. (Shenzhen, CN) ⤷  Subscribe
Chidamide ⤷  Subscribe Histone deacetylase inhibitors Orchid Chemicals & Pharmaceuticals Limited (Chennai, IN) ⤷  Subscribe
>Drugname>Patent Number>Patent Title>Patent Assignee>Estimated Expiration
Showing 1 to 3 of 3 entries

International Patents for Chidamide

DrugnameCountryDocument NumberEstimated ExpirationRelated US Patent
Chidamide Australia AU2008309269 1989-12-31 ⤷  Subscribe
Chidamide Canada CA2702536 1989-12-31 ⤷  Subscribe
Chidamide European Patent Office EP2205563 1989-12-31 ⤷  Subscribe
>Drugname>Country>Document Number>Estimated Expiration>Related US Patent
Showing 1 to 3 of 3 entries

Development Update and Market Projection for Chidamide (Epidaza®)

Introduction to Chidamide (Epidaza®)

Chidamide, also known as Tucidinostat and marketed under the trade name Epidaza®, is a groundbreaking drug developed by Shenzhen Chipscreen Biosciences Co., Ltd. It is the first oral subtype-selective histone deacetylase (HDAC) inhibitor and has garnered significant attention for its innovative mechanism of action and diverse clinical applications.

Approval and Clinical Indications

Recent Approvals

In a significant development, Chidamide combined with the R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) has been approved by the National Medical Products Administration (NMPA) for the treatment of previously untreated diffuse large B-cell lymphoma (DLBCL) with positive MYC and BCL2 expression. This approval is based on a randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial known as the DEB trial (NCT04231448)[1][4].

Existing Indications

Since its initial approval in China in December 2014 for the treatment of peripheral T-cell lymphoma, Chidamide has been approved for multiple indications globally. These include adult T-cell leukemia/lymphoma (ATLL), breast cancer, and other hematological malignancies. In March 2023, it was also approved for postmenopausal women with locally advanced or metastatic breast cancer[4].

Clinical Trials and Efficacy

DEB Trial

The DEB trial, the first Phase III registered clinical study focusing on first-line treatment of MYC/BCL2 dual expression DLBCL, demonstrated that the combination of Chidamide and R-CHOP significantly improved the complete response rate (CRR) compared to the R-CHOP regimen alone. This trial's interim analysis, conducted by the Independent Data Monitoring Committee (iDMC), confirmed that the efficacy and safety indicators set by the protocol were achieved[1][4].

Safety and Efficacy

The combination of Chidamide with R-CHOP has shown promising results in improving survival benefits for patients with DLBCL, particularly those with dual expression of BCL2 and MYC proteins. Dr. Xianping Lu, Chairman and General Manager of Chipscreen Biosciences, highlighted that this combination brings new hope and better survival benefits to patients, addressing a long-standing therapeutic gap in DLBCL treatment[1][4].

Market Projection

Global Market Size

The global Chidamide sales market is projected to experience significant growth. As of 2023, the market size was valued at approximately USD 527 million and is expected to reach around USD 1,234 million by 2032[2].

Growth Drivers

Several factors are driving the growth of the Chidamide market:

  • Increasing Incidence of Cancer: The rising incidence of cancers, including hematological malignancies and solid tumors, is a major driver.
  • Expanding Indications: Chidamide's approval for various indications, including breast cancer and DLBCL, is broadening its market reach.
  • Competitive Pricing: Compared to other HDAC inhibitors, Chidamide's relatively lower cost is making it more accessible in the Asia Pacific region and other markets[3].

Market Segmentation

The global epigenetic drugs and diagnostics market, which includes HDAC inhibitors like Chidamide, is segmented by diagnostic technology, mechanism of action, and geography. HDAC inhibitors are expected to grow at a faster rate over the forecast period, driven by their application in hematological neoplasms and emerging non-oncology indications such as HIV infection, muscular dystrophies, and neurodegenerative diseases[3].

Geographical Trends

While North America and Europe currently dominate the epigenetic drugs and diagnostics market, the Asia Pacific region is anticipated to grow exponentially due to rising disease incidences and an aging population. This trend is expected to further boost the sales of Chidamide in these regions[3].

Competitive Landscape

Market Share and Growth

Among HDAC inhibitors, Chidamide is anticipated to grow at the fastest rate due to its wide range of approved indications, lower cost, and manufacturing licenses in the Asia Pacific region. Other HDAC inhibitors, such as vorinostat (Zolinza) and panobinostat (Farydak), also hold significant market shares but are not growing as rapidly as Chidamide[3].

Pipeline Developments

Chipscreen Biosciences continues to innovate with multiple original drug product lines in various disease areas, including oncology, metabolic diseases, autoimmune diseases, central nervous system disorders, and antiviral therapies. This robust pipeline, including drugs like chiauranib (Ibcasertib) and CS12192, positions the company for continued growth and market expansion[1].

Conclusion

Chidamide (Epidaza®) has established itself as a pivotal drug in the treatment of various cancers, particularly hematological malignancies. With recent approvals and ongoing clinical trials, it is poised for significant market growth. The drug's unique mechanism of action, competitive pricing, and expanding indications make it a promising candidate in the global epigenetic drugs market.

Key Takeaways

  • Approval for DLBCL: Chidamide combined with R-CHOP has been approved for treating previously untreated DLBCL with positive MYC and BCL2 expression.
  • Clinical Efficacy: The DEB trial demonstrated improved complete response rates compared to the R-CHOP regimen alone.
  • Market Growth: The global Chidamide sales market is projected to reach USD 1,234 million by 2032.
  • Competitive Advantage: Chidamide's lower cost and wide range of approved indications drive its market growth.
  • Geographical Expansion: The Asia Pacific region is expected to be a key growth area due to rising disease incidences and an aging population.

FAQs

What is Chidamide (Epidaza®)?

Chidamide, or Tucidinostat, is an oral subtype-selective histone deacetylase (HDAC) inhibitor developed by Shenzhen Chipscreen Biosciences Co., Ltd.

What are the recent approvals for Chidamide?

Chidamide combined with R-CHOP has been approved for the treatment of previously untreated diffuse large B-cell lymphoma (DLBCL) with positive MYC and BCL2 expression.

What is the significance of the DEB trial?

The DEB trial is the first Phase III registered clinical study focusing on first-line treatment of MYC/BCL2 dual expression DLBCL and showed significant improvement in complete response rates when Chidamide is combined with R-CHOP.

What is the projected market size for Chidamide by 2032?

The global Chidamide sales market is expected to reach around USD 1,234 million by 2032.

Why is Chidamide growing faster than other HDAC inhibitors?

Chidamide's growth is driven by its wide range of approved indications, lower cost, and manufacturing licenses in the Asia Pacific region.

Sources

  1. Chipscreen Biosciences: National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma[1].
  2. Dataintelo: Global Chidamide Sales Market Research Report 2032[2].
  3. iHealthcareAnalyst: Global Epigenetic Drugs and Diagnostics Market $19.7 Billion by 2031[3].
  4. Chipscreen Biosciences: National Medical Products Administration (NMPA) Approves Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma[4].

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.